Sexual behavior and its relationship to ovarian hormones in the menopause

The perimenopause and sexual functioning

Sexual functioning is an important component of women's lives. Sexual functioning, however, declines with age, and there is much debate about the contribution of menopause to sexual activity and functioning...The present article covers cross-sectional and longitudinal community-based research on sexual functioning during the perimenopause. .The.article addresses the relative contributions of perimenopause and other.factors (e.g., relationship with partner, previous sexual enjoyment, psychosocial.factors and health) to sexual functioning.

A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder

OBJECTIVES

To assess the safety and efficacy of 10 mg topical testosterone therapy daily (2 cm Andro-Feme cream) as a treatment for low sexual desire in postmenopausal hysterectomized women who were already on transdermal estrogen.

METHODS

A double-blind, randomized, placebo-controlled, cross-over study (each period being of 3 months' duration) was performed in the research center of a tertiary referral women's hospital. Thirty-six menopausal healthy women were recruited who had undergone a hysterectomy, who were not depressed, were in a stable relationship and who fulfilled diagnostic criteria for low sexual desire, as measured by the Brief Index of Sexual Function for Women (BISF-W).

MAIN OUTCOME MEASURES

The primary outcome measure was improvement in the sexuality score as measured by a validated tool (BISF-W); secondary measures were sub-scores of the BISF-W, effect on mood and energy, lipids and testosterone levels.

RESULTS

Testosterone cream significantly improved sexual desire, frequency of sex, receptivity and initiation as measured by the BISF-W score. It did not change mood, energy, lipids, blood pressure or weight over the study period.

CONCLUSIONS

Testosterone cream significantly improved sexual scores in menopausal women with low sexual desire. It was effective, easy to use and had no side-effects over the 3-month period of active treatment. It offers a novel and acceptable method of administering testosterone to menopausal women.

Psychoimmunological effects of dioscorea in ovariectomized rats: role of anxiety level

BACKGROUND

Anxiety levels in rats are correlated with interleukin-2 (IL-2) levels in the brain. The aim of the present study was to investigate the effects of dioscorea (wild yam), a Chinese medicine, on emotional behavior and IL-2 levels in the brain of ovariectomized (OVX) rats.

METHODS

One month after ovariectomy, female Wistar rats were screened in the elevated plus-maze (EPM) test to measure anxiety levels and divided into low anxiety (LA) and high anxiety (HA) groups, which were then given dioscorea (250, 750, or 1500 mg/kg/day) by oral gavage for 27 days and were tested in the EPM on day 23 of administration and in the forced swim test (FST) on days 24 and 25, then 3 days later, the brain was removed and IL-2 levels measured.

RESULTS

Compared to sham-operated rats, anxiety behavior in the EPM was increased in half of the OVX rats. After chronic dioscorea treatment, a decrease in anxiety and IL-2 levels was observed in the HA OVX rats. Despair behavior in the FST was inhibited by the highest dosage of dioscorea.

CONCLUSION

These results show that OVX-induced anxiety and changes in neuroimmunological function in the cortex are reversed by dioscorea treatment. Furthermore, individual differences need to be taken into account when psychoneuroimmunological issues are measured and the EPM is a useful tool for determining anxiety levels when examining anxiety-related issues.

Sexual functioning and practices in a multi-ethnic study of midlife women: baseline results from SWAN

This study examined the sexual practices and function of midlife women by ethnicity (African American, Caucasian, Chinese, Hispanic, Japanese) and menopausal status. Sexual behavior was compared in 3,262 women in the baseline cohort of SWAN. Participants were 42 to 52 years old, premenopausal or early perimenopausal, and not hysterectomized or using hormones. Analysis used multivariate proportional odds regression. In our sample, 79% had engaged in sex with a partner in the last 6 months, and a third considered sex to be very important. Common reasons for no sex (n = 676) were lack of partner (67%), lack of interest (33%), and fatigue (16%). Compared with Caucasians, Japanese and Chinese women were less likely, and African Americans more likely, to report sex as very important (p < 0.005). Significant ethnic differences were found for frequency of all practices. Perimenopause status was associated only with higher frequencies of masturbation and pain during intercourse.

Effects of hormone replacement therapy on sexuality in postmenopausal women in a mideast country

OBJECTIVE

During the postmenopausal period, sexual interest and activity seem to decline, as part of the menopausal effect of oestrogen deficiency. The aim of this study was to evaluate other factors that could contribute to sexual dysfunction and the effect of hormone replacement therapy among postmenopausal women in Kuwait.

METHOD

Between June 1992, and June 1994, details of sexual history were compiled from 261 postmenopausal women that attended the Menopause Clinic at the Maternity Hospital, Kuwait. The effect of hormone replacement was analysed from the sexual history and the bacteriology of the lower genital tract.

RESULTS

About 71% of the 261 postmenopausal women were still sexually active. Among those not sexually active, 38% had loss of interest, 22% because of divorce or death of husband, 20% from loss of interest by husband, and in 13% because the husbands had impotence from medical problems. Of the sexually active women, 41.1% had reduced libido. Contributing factors included vaginal symptoms like dyspareunia and vaginal dryness, vaginal infection, disturbances in the premenopausal menstrual pattern and disharmony with husbands. About 23 to 45% of the postmenopausal women with oestrogen replacement therapy, had significant relief of their symptoms of sexual dysfunction. Vasomotor symptoms had better response compared to sexual dysfunction (p < 0.01). Natural oestrogen gave slightly better relief of symptoms of sexual dysfunction than other forms of oestrogen therapy. Livial gave complete relief of dyspareunia and vaginal dryness in 9.1% and 3.9% respectively, but none of those with libido and vaginal discharge had any relief.

CONCLUSION

There is a decline in sexual response and activity in postmenopausal women in Kuwait. This is however, multifactorial in origin. Although oestrogen replacement therapy gives significant relief in symptoms of sexual dysfunction, other contributory factors should always be evaluated.

Perimenopause: the transition into menopause

With an ever-accumulating body of knowledge about menopause has come the realization that the transition into menopause, specifically the perimenopausal period, is a process occurring over a period of years. We now know that the majority of women do not move from a time of regular menses to an abrupt cessation of menses. Rather, they experience perimenopause, a time of menstrual irregularity defined by changes in the length of the menstrual cycle and/or changes in level of discomfort associated with menses. We also know now that hormonal levels during the perimenopausal period may fluctuate more intensely, precipitating vasomotor and other symptoms. There is a tremendous need to educate women and their health care providers about the stages of the menopausal process. Such education will foster understanding of when women can expect the onset of perimenopausal symptoms. Health care providers should assist women with their questions and concerns as they move through this time of transition.

Decreased sexual interest and its relationship to body build in postmenopausal women

OBJECTIVES

The relationship between body build, androgen levels and changes in sexual interest after menopause was investigated in 171 postmenopausal women from Vienna, Austria.

METHODS

All women were interviewed using a structured questionnaire. Body build was determined by employing five absolute body dimensions and four anthropometric indices.

RESULTS

Body weight, as well as the amount of subcutaneous centripetal fat (such as in the chest, waist and hip region), were statistically significantly related to the degree of reduced sexual interest. Corpulent and heavy women suffered far more frequently from a severe decrease in sexual interest after menopause. Statistically significant associations between androgen levels and decrease in sexual interest could not be demonstrated.

CONCLUSIONS

Reduced sexual interest is associated with a kind of body type not corresponding to the culture-specific beauty ideals of our society, first of all evident in women whose menopause occurred relatively early.

Predictors of menopausal symptoms: psychosocial aspects

The most relevant factors influencing a woman's quality of life during the menopausal transition appear to be her previous emotional and physical health, her social situation, her experience of stressful life events (particularly bereavements and separations), as well as her beliefs about the menopause. Specific predictors of vasomotor symptoms include surgical menopause and possibly current cigarette smoking. The role of stress, past menstrual problems and reports of hot flushes earlier in life as predictors requires further study. There are considerable cultural differences in the reporting of vasomotor symptoms which may be explained by the meaning ascribed to them and the value of older women in societies, as well as possible dietary, lifestyle and genetic differences. Those who seek medical help for menopausal problems tend to report more physical and psychological problems in general. They are more likely to be under stress and to hold particular beliefs about the menopause. These personal and social issues need to be addressed in their own right and should not be automatically attributed to the menopause. Clinical psychologists and counsellors, ideally working as part of the team, can help women and couples to clarify the nature of the problems and to help them to explore solutions. In contrast to childbirth, preparation for the menopause has been neglected in the development of services, as well as in research (Notelovitz, 1988; Hunter, 1990c). The studies reviewed here do suggest some pointers for health promotion; these are being evaluated in a current study by Hunter and Liao and can be summarized as follows: 1. Providing balanced information about the menopause, to women and their families. 2. Discussion of attitudes towards the menopause, with reassurance of overly pessimistic beliefs. 3. Health promotion sessions focusing upon diet, exercise and smoking (factors which are associated with general health and the development of osteoporosis). 4. Stress management sessions. 5. Group discussion of personal, health and social issues met by women during midlife.

Emotional well-being, sexual behaviour and hormone replacement therapy

Improvements in the design of epidemiological studies of the climacteric and postmenopause have been made in the past 25 years. But more complex theoretical models are necessary if we are to give due emphasis to the influence of psychological, social, cultural and hormonal factors and their interactions. The majority of studies show that emotional problems are not more prevalent during the climacteric and postmenopause and that psychosocial factors, such as stressful life-events, are more likely causes of emotional distress during mid-life. Vaginal dryness increases in postmenopausal women but there are varied reasons for changes in other aspects of sexual behaviour which require further research. While estrogen may have a "mental tonic" effect when prescribed in high doses, HRT does not appear to have a significant effect upon mood or sexual behaviour over and above placebo effects and the relief from vasomotor and vaginal symptoms.